HomeCompareARCVF vs PFE

ARCVF vs PFE: Dividend Comparison 2026

ARCVF yields 3.66% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARCVF wins by $1126.75M in total portfolio value
10 years
ARCVF
ARCVF
● Live price
3.66%
Share price
$30.77
Annual div
$1.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1126.80M
Annual income
$1,070,553,540.61
Full ARCVF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ARCVF vs PFE

📍 ARCVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARCVFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARCVF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARCVF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARCVF
Annual income on $10K today (after 15% tax)
$310.77/yr
After 10yr DRIP, annual income (after tax)
$909,970,509.52/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ARCVF beats the other by $909,948,189.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARCVF + PFE for your $10,000?

ARCVF: 50%PFE: 50%
100% PFE50/50100% ARCVF
Portfolio after 10yr
$563.43M
Annual income
$535,289,899.67/yr
Blended yield
95.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ARCVF
No analyst data
Altman Z
4.0
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARCVF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARCVFPFE
Forward yield3.66%6.13%
Annual dividend / share$1.13$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$1126.80M$49.6K
Annual income after 10y$1,070,553,540.61$26,258.71
Total dividends collected$1122.74M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ARCVF vs PFE ($10,000, DRIP)

YearARCVF PortfolioARCVF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,431$731.23$9,153$693.39+$2.3KARCVF
2$13,794$1,562.41$8,593$849.25+$5.2KARCVF
3$18,283$3,523.97$8,336$1,066.78+$9.9KARCVF
4$28,294$8,730.71$8,437$1,384.80+$19.9KARCVF
5$55,529$25,254.16$9,013$1,875.40+$46.5KARCVF
6$152,057$92,640.99$10,306$2,680.72+$141.8KARCVF
7$636,875$474,173.97$12,820$4,101.38+$624.1KARCVF
8$4,393,665$3,712,209.34$17,673$6,826.70+$4.38MARCVF
9$52,569,931$47,868,709.49$27,543$12,591.86+$52.54MARCVF
10$1,126,803,367$1,070,553,540.61$49,560$26,258.71+$1126.75MARCVF

ARCVF vs PFE: Complete Analysis 2026

ARCVFStock

Arcadis NV operates as a design and consultancy firm for natural and built assets worldwide. The company operates through four segments: Europe & Middle East, The Americas, Asia Pacific, and CallisonRTKL. It offers architectural based design consultancy services; and asset management services, such as asset management strategy and planning, asset management decision making and operational optimization, life cycle planning and asset management systems, asset information/condition assessment, risk and review, organization and people, and asset management/O&M. The company also provides business advisory services, including asset strategy and performance, business transformation and resiliency, investment and finance, operations and maintenance, and technology and information; cost and commercial management services; and design and engineering solutions for highways, railways, bridges, tunnels, power utilities, water utilities, ports and waterways, geotechnics, architecture, and structures, as well as building mechanical, electrical, and plumbing. In addition, it offers digital environmental health safety and sustainability, environmental restoration, and project management solutions. Further, the company provides mobility solutions for connected highways, intelligent rail and transit, integrated airports, and new mobility; places solutions; resilience solutions, including climate adaption, energy transition, enviro socio permitting, environmental restoration, sustainable advisory, sustainable operations, and water optimization; and water supply and treatment, distribution, resource management, and industrial water and wastewater services. It serves industrial manufacturing, technology, property and investment, contractors, and energy and resources sectors. The company was formerly known as Heidemij NV and changed its name to Arcadis N.V. in October 1997. Arcadis NV was founded in 1888 and is headquartered in Amsterdam, the Netherlands.

Full ARCVF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ARCVF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARCVF vs SCHDARCVF vs JEPIARCVF vs OARCVF vs KOARCVF vs MAINARCVF vs JNJARCVF vs MRKARCVF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.